Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Executive Summary
Company plans to meet with caregivers and consider other options before moving forward.
You may also be interested in...
At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
Best Defense Is Good Offense: PhRMA Wants PBMs To 'Share The Savings'
PhRMA ad campaign targets US payer practice of using drug rebate dollars for general premium and cost sharing reductions and not to lower the cost of specific prescription fills.
Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug
Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.